# Oncoceutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncoceutics

- Industry: Pharmaceuticals
- Headquarters: Philadelphia, US
- Website: www.oncoceutics.com
- Latest round: Series A (Oct 6, 2015)
- Investors on record: 1

## About

Oncoceutics, Inc. specializes in developing innovative cancer therapeutics designed to enhance existing treatment options, focusing on small molecular compounds that improve patient outcomes across various malignancies.Oncoceutics, Inc. is a biopharmaceutical company based in Philadelphia, US, founded in 2009. The company is dedicated to creating therapeutics that target cancer treatment. The CEO and co-founder, Lee Schalop, has a history in drug development and oncology. In January 2021, Chimerix, Inc. acquired Oncoceutics from Calvert Research LLC and Spring Mountain Capital. The company has completed a total of 5 deals, the most recent being a GRANT round that raised USD 0.22 mn from the National Cancer Institute.Oncoceutics specializes in the development of innovative therapeutics for cancer treatment, focusing primarily on the design and commercialization of small molecular compounds aimed at enhancing the efficacy of existing cancer therapies. Their core product offerings include targeted therapies that disrupt cancer cell proliferation and survival mechanisms, thereby improving patient outcomes in various malignancies. The company serves healthcare providers, hospitals, and pharmaceutical partners, and operates primarily in North America, Europe, and select regions in Asia.Oncoceutics generates revenue through strategic partnerships and collaborations with healthcare institutions, pharmaceutical companies, and research organizations. Transactions typically involve licensing agreements and co-development partnerships for their proprietary therapeutics. The company’s revenue model includes milestone payments and royalties associated with the commercialization of its flagship products, aligning pricing structures with the value provided to healthcare providers.With its most recent funding round in January 2021, Oncoceutics will utilize the resources from the acquisition to accelerate the development of ONC201 for glioma patients, addressing urgent treatment needs. The company aims to expand its market presence in oncology by enhancing its product offerings and penetrating additional geographic regions. As part of its strategy, Oncoceutics is focused on developing upcoming therapies to introduce to the market, further strengthening its position in the oncology landscape.

## Funding rounds

- Series A, Oct 6, 2015 — Spring Mountain Capital

## Investors

- Spring Mountain Capital (https://capitalatlas.ai/funds/spring-mountain-capital) — Series A